Successful Treatment of Primary Hyperoxaluria Type 2 with a Combined Liver and Kidney Transplant

Kareem M. Genena; David J. Sas; Dawn S. Milliner; John C. Lieske

doi:10.1016/j.ekir.2023.03.013

Successful Treatment of Primary Hyperoxaluria Type 2 with a Combined Liver and Kidney Transplant

Kareem M. Genena, David J. Sas, Dawn S. Milliner, John C. Lieske

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Journal	Kidney International Reports
DOIs	https://doi.org/10.1016/j.ekir.2023.03.013
State	Accepted/In press - 2023

ASJC Scopus subject areas

Nephrology

Access to Document

10.1016/j.ekir.2023.03.013

Cite this

@article{8597f8394d6c490cacc7ddc6e9d6373e,

title = "Successful Treatment of Primary Hyperoxaluria Type 2 with a Combined Liver and Kidney Transplant",

author = "Genena, {Kareem M.} and Sas, {David J.} and Milliner, {Dawn S.} and Lieske, {John C.}",

note = "Funding Information: This work is partly supported by a grant from the National Institute of Diabetes and Digestive and Kidney Diseases ( DK133171 ). In addition, this work was also funded by the Rare Kidney Stone Consortium (U54DK83908), which is part of Rare Diseases Clinical Research Network, an initiative of the Office of Rare Diseases Research, National Center for Advancing Translational Sciences. This consortium is funded through collaboration between National Center for Advancing Translational Sciences, and the National Institute of Diabetes and Digestive and Kidney Diseases. This work is also supported by funds from the Oxalosis and Hyperoxaluria Foundation, and Mayo Foundation. Those funding the study had no role in study design, analysis, reporting, or decision to submit the manuscript for publication. Funding Information: DSM has received consulting fees from OxThera, Dicerna, Allena, Alnylam, and Synlogic; and grant support from the NIDDK, OxThera, Dicerna, and Alnylam. JCL receives consulting fees from the American Board of Internal Medicine, Alnylam, Federation Bio, OxThera, Precision Biosciences, Cantero/Bridgebio, Dicerna, Synlogic, Orfan, Intellia, Mirium, Biomarin, and Novobiome; and grant support from Alnylam, Allena, Retrophin, Synlogic, Novobiome, OxThera, NIDDK, and Dicerna. DJS has received grant funding from Alnylam and Dicerna, as well as consulting fees from Advicenne. KMG declared no conflict of interest. ",

year = "2023",

doi = "10.1016/j.ekir.2023.03.013",

language = "English (US)",

journal = "Kidney International Reports",

issn = "2468-0249",

publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Successful Treatment of Primary Hyperoxaluria Type 2 with a Combined Liver and Kidney Transplant

AU - Genena, Kareem M.

AU - Sas, David J.

AU - Milliner, Dawn S.

AU - Lieske, John C.

N1 - Funding Information: This work is partly supported by a grant from the National Institute of Diabetes and Digestive and Kidney Diseases ( DK133171 ). In addition, this work was also funded by the Rare Kidney Stone Consortium (U54DK83908), which is part of Rare Diseases Clinical Research Network, an initiative of the Office of Rare Diseases Research, National Center for Advancing Translational Sciences. This consortium is funded through collaboration between National Center for Advancing Translational Sciences, and the National Institute of Diabetes and Digestive and Kidney Diseases. This work is also supported by funds from the Oxalosis and Hyperoxaluria Foundation, and Mayo Foundation. Those funding the study had no role in study design, analysis, reporting, or decision to submit the manuscript for publication. Funding Information: DSM has received consulting fees from OxThera, Dicerna, Allena, Alnylam, and Synlogic; and grant support from the NIDDK, OxThera, Dicerna, and Alnylam. JCL receives consulting fees from the American Board of Internal Medicine, Alnylam, Federation Bio, OxThera, Precision Biosciences, Cantero/Bridgebio, Dicerna, Synlogic, Orfan, Intellia, Mirium, Biomarin, and Novobiome; and grant support from Alnylam, Allena, Retrophin, Synlogic, Novobiome, OxThera, NIDDK, and Dicerna. DJS has received grant funding from Alnylam and Dicerna, as well as consulting fees from Advicenne. KMG declared no conflict of interest.

PY - 2023

Y1 - 2023

UR - http://www.scopus.com/inward/record.url?scp=85152553954&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85152553954&partnerID=8YFLogxK

U2 - 10.1016/j.ekir.2023.03.013

DO - 10.1016/j.ekir.2023.03.013

M3 - Article

AN - SCOPUS:85152553954

SN - 2468-0249

JO - Kidney International Reports

JF - Kidney International Reports

ER -

Successful Treatment of Primary Hyperoxaluria Type 2 with a Combined Liver and Kidney Transplant

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this